




PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61K 31/557, A61M 31/00		A2	(11) International Publication Number: WO 99/30718
			(43) International Publication Date: 24 June 1999 (24.06.99)
(21) International Application Number: PCT/US98/26609 (22) International Filing Date: 15 December 1998 (15.12.98) (30) Priority Data: 08/992,946 18 December 1997 (18.12.97) US 09/005,087 9 January 1998 (09.01.98) US 09/038,378 11 March 1998 (11.03.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/992,946 (CIP) Filed on 18 December 1997 (18.12.97) (71)(72) Applicant and Inventor: SCOTT, Nathan, Earl [US/US]; 610 Laguna Road, Fullerton, CA 92835 (US). (74) Agents: RAM, Michael, J. et al.; Loeb & Loeb LLP, Suite 2200, 10100 Santa Monica Boulevard, Los Angeles, CA 90067 (US).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published Without international search report and to be republished upon receipt of that report.
(54) Title: PROSTAGLANDIN E <sub>2</sub> /F <sub>2α</sub> COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL			
(57) Abstract <p>A method of treating and a composition for treating erectile dysfunction in a male patient or female sexual arousal dysfunction, comprising the step of administering to the patient a unit dose of a formulation comprising an effective amount of a prostaglandin, namely prostaglandin E<sub>1</sub>, prostaglandin E<sub>2</sub>, or pharmaceutically acceptable salts or derivatives thereof, wherein the prostaglandin is formulated with a small amount of prostaglandin F<sub>2α</sub> together with a pharmaceutically acceptable delivery medium and/or a lubricant. The method also contemplates PGE<sub>2</sub> with phentolamine mesylate, with or without PGF<sub>2α</sub>.</p>			



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**PROSTAGLANDIN E<sub>2</sub>/F<sub>2α</sub> COMBINATION FOR TREATING IMPOTENCE  
AND ENHANCING SEXUAL AROUSAL**Background of the InventionArea of the Art

5           This application is a continuation-in-part of, and claims priority based  
on U.S. Serial Number 09/038,378 filed March 11, 1998, U.S. Serial Number  
09/005,087 filed January 9, 1998, and U.S. Serial Number 08/992,946 filed  
December 18, 1997, all of which are continuations-in-part of Serial Number  
08/090,483 filed July 12, 1993, now U.S. Patent 5,708,031 issued January  
10   13, 1998 which is a continuation of Serial Number 07/860,107 filed March 30,  
1992, which is a continuation of Serial Number 07/725,350 filed July 3, 1991.

          The present invention relates to the treatment of impotence in males,  
enhancement of sexual arousal in females and devices for delivering  
pharmaceutical compositions to treat impotence in males and sexually  
15   stimulate females. In particular, the invention relates to the use of  
prostaglandin PGE<sub>2</sub> and/or PGF<sub>2α</sub> in the treatment of sexual dysfunction.

          In excess of about 10 million men in the United States alone exhibit  
sufficient erectile dysfunction that they can be characterized as effectively  
impotent. A significant number of men additionally suffer from an inability to  
20   develop an erection which may not meet the clinical definition of impotence  
but may not be satisfactory to their desires or those of their partner to provide  
mutually satisfactory sexual intercourse. Impotence in the human male can  
arise from a variety of psychological and physiological etiologies. For  
example, long term diabetes, damage to the spinal cord, multiple sclerosis, or  
25   nerve damage resulting for example from lower abdomen or prostate surgery,  
and advancing age can result in impotence. Additionally, there are  
psychological causes for impotence. For differing reasons, each of the  
foregoing result in an inability to pressurize the corpora cavernosa, which can  
result in turn from either an insufficient arterial inflow on the supply side, or an  
30   insufficient increase in the venous output resistance to blood flow.

          A wide variety of mechanical means have been provided, in an effort to  
overcome erectile dysfunction. For example, United States Patent No.

- 2 -

4,596,242 to Fischell discloses a surgically implantable hydraulic system, having a fluid reservoir and pressure generator, a patient manipulable valve, a pressure reservoir and a distensible member responsive to actuation of the valve. A variety of other prior art mechanical implants and other devices for this purpose are described in the Background of the Invention section of the United States Patent No. 4,596,242.

In addition to the mechanical efforts to overcome erectile dysfunction, pharmaceutical approaches have been tried as well. For example, prostaglandin E<sub>1</sub> has been observed to produce erection in some cases, by direct percutaneous injection into the penis or as a meltable pellet placed in the urethra (U.S. Patent Nos. 5,773,020; 5,474,535; 5,242,391). PGE<sub>1</sub> in a drug composition known as "trimix", has also been injected directly into the corpus cavernosa to treat impotence. One of the additional ingredients in trimix is phentolamine mesylate.

Most recently Pfizer has made sildenafil citrate available in oral dosages as a treatment for impotence under the trade name, Viagra. However, Viagra is contraindicated for use by men with cardiac disease, death in cardiac patients during or following intercourse has been indicated as a possible side effect, and interaction with nitroglycerine may cause immediate death. In addition, a new warning has been added to labeling for Viagra warning of a possible occurrence of priapism. Also since sildenafil citrate is administered orally, the effect of the drug is systemic and not restricted, as in direct delivery to the penis, to a localized response.

Further, both PGE<sub>1</sub> and Viagra have been shown to be effective in only certain causes of impotence. In particular, neither drug appears to be particularly effective to treat impotence resulting from surgical procedures on the prostate.

Still further, the needs for localized drugs to treat female sexual deficiencies have not been adequately addressed by presently available products. It is estimated that there are ten million women in the United States who suffer from female sexual arousal dysfunction.

- 3 -

Therefore, there remains a need for an improved treatment of erectile dysfunction in the male and arousal dysfunction in the female. Surgical implantation and/or repeated injections range from disfavored to medically disadvantageous, and do not, as a whole, provide a satisfactory solution to the problem. From a patient usability standpoint, erectile dysfunction would most advantageously be treated on a self-administration basis, without the need of surgical intervention or repeated injections of a pharmaceutical agent. This problem has been addressed by the use of PGE<sub>2</sub> as claimed in my U.S. Patent 5,708,031. However, some patients on using urethral placement of PGE<sub>2</sub> materials have experienced urethral burning and cavernous sinus aching within the genital area. This unpleasant sensation is also experienced on use of PGE<sub>1</sub>. To counteract this side effect an anesthetic may be added to the prostaglandin formulation. However, this in turn requires using an increased quantity of the prostaglandin.

Further, the prior gel formulation and the PGE<sub>1</sub> pellet requires the delivery of a greater volume of treatment composition than may be desired. Still further, it would be a significant improvement if a simple and safe composition is available for application to the female external genitalia which would increase sensitivity, enhance lubrication and result in local vasodilation and engorgement of external and meatal tissue all of which would enhance the female sexual arousal and experience.

Therefore, there is a need for a PGE<sub>2</sub> formulation which avoids these negative sensations but does not interfere with the effectiveness of the PGE<sub>2</sub> for treatment of impotence.

#### Summary of the Invention

In accordance with one aspect of the present invention, there is provided method of treating erectile dysfunction in a male patient, comprising the step of administering to the patient a unit dose of a formulation comprising an erectile dysfunction treating amount of prostaglandin E<sub>2</sub> compound, or pharmaceutically acceptable salts or derivatives thereof. The prostaglandin

- 4 -

E<sub>2</sub> compound is preferably formulated together with a pharmaceutically acceptable delivery medium, which may comprise local anesthetic agents and/or a lubricant. Preferably, the anesthetic agent comprises lidocaine. The dose of PGE<sub>2</sub> may be in the form of a urethra sized suppository meltable at body temperature, coated on a removable wand, carried on and/or in a porous, non-absorbable wand sized for easy placement into and withdrawal from the urethra, or in physiologically acceptable carrier (saline or water) placed in the urethra via a small diameter tube. The prostaglandin E<sub>2</sub> compound can also be formulated with a small amount of prostaglandin F<sub>2α</sub> and/or phentolamine mesylate together with a pharmaceutically acceptable delivery medium and/or a lubricant.

A unit dose of the formulation in accordance with the present invention will typically be less than about 5 cc in volume, preferably less than about 3 cc and most preferably below about 1 cc. The amount of active ingredient in a unit dose will typically be within the range of from about 0.1 mg to about 4.0 mg. More preferably, the amount of prostaglandin E<sub>2</sub> in a unit dose will be within the range of from amount 0.6 mg to about 3.6 mg. This is more than the amount of PGE<sub>1</sub> required for a beneficial result. However, tests show that the results obtained from use of PGE<sub>1</sub> are much less satisfactory than when PGE<sub>2</sub> is used. Further, if anesthetic, such as lidocaine is added to the formulation to minimize or eliminate burning, 1.2 mg to about 3.6 mg of PGE<sub>2</sub> may be required. It has now been found that adding prostaglandin F<sub>2α</sub> in amounts of about 0.1 micrograms (0.1 μg) to about 2.0 μg to either prostaglandin E<sub>2</sub> or E<sub>1</sub> formulations prevents the burning and aching without noticeably interfering with effectiveness of the prostaglandin. A preferred amount is 0.25 μg of PGF<sub>2α</sub> per 1 mg of PGE<sub>2</sub>. It has also been found that adding phentolamine mesylate to this composition further increases the effectiveness of the composition (increased rigidity and increased but controlled longevity).

The administration step of the method in accordance with the present invention comprises the transurethral administration of the unit dose of

- 5 -

formulation. In an embodiment where the formulation comprises a cream, gel form or saline solution, the formulation is preferably transurethraly instilled or inserted such as by extrusion through syringe or unit dose administration packet comprising an elongate tubular administration tip.

5           An alternative delivery procedure comprises the transurethral placement of a unit dose of the formulation using a coated wand or a suppository containing a quantity of the formulation suitable for delivery to the patient within a preset period of time.

10           In an embodiment of the present invention, wherein the administrable form of the formulation comprises a relatively rigid suppository, the suppository can be manually inserted into the distal opening of the urethra.

          A further embodiment provides for urethral insertion of a removable wand, which may be porous, which carries the unit dose in a form which transfers over a controlled period of time through the urethral mucosa.

15           These and further objects and advantages of the present invention will become apparent from the Drawings and Description which follows, considered together with the appended Claims.

#### DRAWINGS

20           These and other features, aspects and advantages of the present invention will become better understood with reference to the following description, appended claims, and accompanying drawings, where:

          Figure 1 is a perspective side view of a first version of the insertable drug delivery device.

          Figure 2 is a cross sectional view taken along line 2-2 of Figure 1.

25           Figure 3 is a side view of a second version of the insertable drug delivery device.

          Figure 4 is an end view of the second version of the insertable drug delivery device.

30           Figure 5 is a side view of a third version of the insertable drug delivery device.

- 6 -

Figure 6 is an left end view of the third version of the insertable drug delivery device.

Figure 7 is an left end view second variation of the third version of the insertable drug delivery device.

5        Figure 8 is a cut away side view of the third version of the insertable drug delivery device of Figure 6 inserted in a carrier.

Figure 9 is a cut away side view of a variation of each of the above versions inserted in a penis.

10       Figure 10 is a partial cutaway view of a device for delivery of a liquid dose of impotence treating drug.


#### Detailed Description of Preferred Embodiments

The prostaglandins are a series of cyclic derivatives of certain unsaturated fatty acids. They are found in a variety of tissues, including the prostate gland, the seminal vesicles, the lungs and the brain. These naturally  
15       occurring prostaglandin are derived by cyclization of 20-carbon unsaturated fatty acids such as arachidonic acid. See Lehninger, Albert L., Biochemistry, 2d ed. (1975), p. 300 (hereinafter "Lehninger").

Carbon atoms of the fatty acid backbone are cyclized to form a characteristic 5-membered ring. The prostaglandin are divided into a number  
20       of groups, including those designated A-F, based on the configuration of the ring structure. Prostaglandin also differ in stereochemistry and in the number of side chain double bonds which are conventionally indicated by a subscript number. Thus, for example, prostaglandin E<sub>2</sub> ("PGE<sub>2</sub>") has the ring configuration characteristic of the E group and contains two side chain double  
25       bonds. The chemical name for PGE<sub>2</sub> is (5Z, 11 $\alpha$ , 13E, 15S)-11, 15-Dihydroxy-9-oxo-prosta-5, 13-dien-1-oic acid and the structural formula of one form is represented in Formula I, below. The molecular formula is C<sub>20</sub>H<sub>32</sub>O<sub>5</sub>.



- 7 -



The biosynthesis of prostaglandin has been well characterized. See, e.g., Lehninger at p. 687. In a typical biosynthetic pathway, exemplified by production of PGE<sub>2</sub>, the essential fatty acid linoleic acid is converted into the 20-carbon arachidonic acid, which is then acted upon by prostaglandin synthase, doxygenase enzyme. Oxygen atoms are added at carbon atoms 9 and 15, and the product is cyclized by formation of a bond between carbon atoms 8 and 12. In the presence of reduced glutathione, this synthesized product undergoes conversion into prostaglandin PGE<sub>2</sub>. Other types of naturally occurring prostaglandins are derived from different polyunsaturated fatty acids.

In about the 1960's, prostaglandin were isolated from a particular species of Caribbean coral, which made them more widely available for research. Catanzarite, Valerian A. and Gary Aisenbrey, Contemporary OB/GYN (October 1987), p. 22 (hereinafter "Catanzarite"). A large number of natural and synthetic analogues of he prostaglandin are now known. Lehninger at 687.

The various different prostaglandins are known to produce often unpredictable effects over a very wide range of biological activities of a hormonal or regulatory nature. Prostaglandin have been reported to both lower and raise blood pressure, to inhibit gastric secretion, dilate bronchi, inhibit lipolysis, antagonize vasopressin-induced anti-diarrhesis, constrict the pupil, increase and decrease the intraocular pressure and produce contraction of the uterus. See, e.g., Ganong, William F., Review of Medical Physiology, 7th ed. (1975), p. 226 (hereinafter "Ganong"). The naturally occurring prostaglandin all appear to be capable of affecting the control of

- 8 -

vascular and other smooth muscle contractions. In the central nervous system, prostaglandin are known to modify responses to certain synaptic transmitters. They have been reported to mimic the actions of some hormones and to inhibit the actions of certain others. See Ganong at 226.

5           Two of the most extensively studied of the prostaglandin are PGE<sub>2</sub>, and PGF<sub>2α</sub>. Both of these molecules are synthesized within the pregnant and non-pregnant uterus. While PGE<sub>2</sub> and PGF<sub>2α</sub> are similar in mediating some effects, they are different with respect to certain others. Both cause uterine contractions, but they predominate at different sites within the uterus – PGE<sub>2</sub>  
10       in the lower uterine segment, PGF<sub>2α</sub> is more important in generating uterine contractions. PGE<sub>2</sub> elevates body temperature, whereas PGF<sub>2α</sub> has no apparent effect on body temperature. PGE<sub>2</sub> is a vasodilator and bronchodilator, while PGF<sub>2α</sub> is a bronchoconstrictor and vasoconstrictor. (See Catanzarite at 21-22.)

15           Prostaglandin have been used in gynecology for pregnancy termination. Preparing the cervix with prostaglandin suppository has been found to reduce the incidence of cervical laceration and significant bleeding (Catanzarite at 22). Synthetic analogues of prostaglandin PGE<sub>2</sub>, such as 16-  
20       16-dimethyl PGE<sub>2</sub> and 9-methylene PGE<sub>2</sub>, have proven useful for the induction of first trimester abortions. Such procedures typically use vaginal suppositories containing 20 milligrams PGE<sub>2</sub> or 3 milligrams 15-methyl PGF<sub>2α</sub>, or by repeated intramyometrial injections of 15-methyl PGF<sub>2α</sub>, or by infusing a PGF<sub>2α</sub>-urea mixture (20 milligrams of PGF<sub>2α</sub> and 40 milligrams of urea in 100  
25       ml of 5% dextrose in water) into the amniotic sac.

25           In obstetrics, prostaglandin have been used for cervical ripening, labor induction and control of post-partum hemorrhage (Catanzarite at 29). For cervical ripening, PGE<sub>2</sub> had been given intravenously, orally and vaginally, but the preferred route is intracervically. A PGE<sub>2</sub> gel is now commercially available in Scandinavia, and another PGE<sub>2</sub> gel is being investigated in the  
30       United States. The PGE<sub>2</sub> gel can also be used for labor induction (3-5 mg of PGE<sub>2</sub>, prepared by blending a 20 mg suppository with 60 mL of lubricating

- 9 -

jelly and using 9-15 mL of the mixture, is placed in the vagina) (Catanzarite at 32). Prostaglandin have also been utilized to control post-partum hemorrhage.

5 Since circulating prostaglandin can be rapidly metabolized in the lungs, liver and kidneys, a number of synthetically modified prostaglandins have been developed that are not metabolized as quickly (See, e.g., Catanzarite at 32).


10 Prostaglandin PGE<sub>2</sub>, also known as the "Prostin E<sub>2</sub>" brand of "dinoprostone," is available from Upjohn Company in the form of a vaginal suppository. Indications and usage reported by Upjohn are (i) termination of pregnancy from the 12th through the 20th gestational week, (ii) evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age, and (iii) in the management of non-metastatic gestational trophoblastic disease (benign hydatidiform mole).  
15 See The Upjohn Co., Prostin E<sub>2</sub> product description 810 994 009, Oct., 1990.

PGE<sub>2</sub> is also available from several sources as a purified, freeze dried or lyophilized product which is readily soluble in saline or distilled water.

Contraindications to the use of prostaglandin PGE<sub>2</sub> include hypersensitivity to dynoprostone, acute pelvic inflammatory disease, or  
20 patients with active cardiac pulmonary renal or hepatic disease. Upjohn notes that although carcinogenic bioassay studies have not been conducted in animals for PGE<sub>2</sub> (because of the limited indication for use and the short duration of administration), there was no evidence of mutagenicity in either the Micronucleus Test or in the Ames Assay. Upjohn also indicates that a  
25 number of adverse reactions may be observed with the use of PGE<sub>2</sub> for abortions. These adverse reactions are related to the contractile effect of PGE<sub>2</sub> on smooth muscle and include vomiting, temperature elevations, diarrhea, nausea, transient diastolic blood pressure decreases, and a number of other effects. Upjohn's vaginal suppository contains 20 mg of PGE<sub>2</sub> in a  
30 mixture of glycerides of fatty acids.

- 10 -

Upjohn markets a (15S)-15-methyl analogue of prostaglandin  $\text{PGF}_{2\alpha}$  under the brand name Hemabate®, also known as "carboprost tromethamine sterile solution." The structural formula of Hemabate® is represented in :



Upjohn reports that Hemabate® is indicated for aborting pregnancy  
5 between the 13th and 20th weeks of gestation, in certain conditions related to  
second trimester abortions, and in the treatment of post-partum hemorrhage.  
See The Upjohn Co., product description 814 350 002, Nov., 1989. For  
abortion, the prostaglandin solution is injected using a syringe and  
administered deep in the muscle. Intramuscular injection is also used for  
10 treating post-partum uterine bleeding.

Upjohn also markets prostaglandin  $\text{PGE}_1$ , as the "Prostin VR Pediatric"  
brand of "alprostadil sterile solution," which is used to temporarily maintain  
the patency of the ductus arteriosus until corrective surgery can be performed  
in neonates having congenital heart defects and who depend upon the patent  
15 ductus for their survival. For the administration of  $\text{PGE}_1$  in neonates, Upjohn  
recommends continuous intravenous infusion into a large vein, or  
administration through an umbilical artery catheter placed at the ductal  
opening. See The Upjohn Co., product description 811 987 004, in  
Physician's Desk Reference, 45th Edition, p.2250 (1991).

20 Quite surprisingly, the inventor herein has discovered that transurethral  
application of  $\text{PGE}_2$  can in many cases provide an effective, reversible  
treatment of erectile dysfunction in human males. Thus, in accordance with  
one embodiment of the present invention,  $\text{PGE}_2$  or a pharmaceutically  
acceptable salt, ester or other derivative thereof is formulated together with a  
25 carrier medium which may comprise any of a variety of additional excipients

- 11 -

or adjuvants into a form suitable for transurethral delivery. One approach is to apply the composition to a wand, which may be either porous or non-porous, in sufficient quantities so that the desired dosage is released and absorbed through the mucosa of the urethra when the coated wand is placed  
5 in the urethra. When an erection of the desired tumescence is obtained the wand is then removed, terminating delivery of the composition, thus significantly reducing the possibility of overdosing. While the formulation may be provided in the form of a meltable suppository, such a delivery means is unsuitable for removal to terminate delivery of the composition and can result  
10 in overdosing as well as the delivery of excess  $\text{PGE}_2$  to the vagina of the partner.

In a second embodiment a suitable amount of a freeze dried  $\text{PGE}_2$  is dissolved in physiological saline or sterile water and placed within the urethra using a short, small diameter catheter. The  $\text{PGE}_2$  absorption is rapid with an  
15 erection, ensuing within 3-5 minutes, persisting for 1-2 hours depending on dosage. However, alternative replacements for the water carrier include creams or gels which can flow at or above room temperature, for example at body temperature.

In accordance with another aspect of the present invention, there is  
20 provided an antidote for reversing the effects of the foregoing  $\text{PGE}_2$  treatment, comprising administration of an antidotal amount of  $\text{PGF}_{2\alpha}$ , or pharmaceutically acceptable salts, esters or derivatives thereof. Preferably, 15-methyl  $\text{PGF}_{2\alpha}$  is utilized for this purpose. This antidote can be delivered in the same manner as discussed above.

25 Preferably, the  $\text{PGE}_2$  or  $\text{PGF}_{2\alpha}$  or combination of  $\text{PGE}_2$  and  $\text{PGF}_{2\alpha}$  with or without other additives, as discussed below, will comprise a cream, gel, or water based solution although a more solid form such as pellets or a rod-shaped suppository body may also be used. In the following described devices or delivery techniques, in each case where  $\text{PGE}_2$  is referred to, it is  
30 contemplated that the  $\text{PGF}_{2\alpha}$  may be substituted for delivery purposes.

- 12 -

These devices are also applicable to delivery of PGE<sub>1</sub> compositions or other impotence treatment drugs.

Administration of the liquid, cream or gel form may be accomplished by transurethral delivery using a syringe without a needle, or with a short blunt  
5 cannula attached. The liquid, gel or cream forms are preferably provided in unit dose amounts for self administration by the patient. For this purpose, compressible unit dose packages are preferably provided with an elongate tubular delivery spout, sized for transurethral insertion. Following  
transurethral installation of any of the liquid, gel or cream forms, the distal end  
10 of the urethra is preferably occluded, such as by manual pressure for up to several minutes, to permit sufficient dwell time for absorption.

A typical male urethra in a flaccid penis is from about 2.5 cm to about 8 cm and the typical diameter of the urethra is from about 1 mm to about 3 mm. Accordingly, the wand with PGE<sub>2</sub> and/or PGF<sub>2α</sub> applied has a diameter  
15 approximating the urethra diameter or slightly larger so that the outer surface of the wand is in intimate contact with the mucosal lining of the urethra or swells when inserted. The typical length of the insertable portion of the wand is from 20% to 90% of the patients' urethra in the flaccid state, preferred 25%-  
40% with some or all of the insertable portion coated with PGE<sub>2</sub>. The wand  
20 also has an external portion or length for grasping between the users fingers for placement and removal. This portion may be of a larger diameter or a flange may be positioned between the insertable portion and the exterior portion to prevent the wand from being inserted too far into the urethra.

For delivery of the PGE<sub>2</sub> dissolved in saline or sterile water, solution, a  
25 catheter of about 1.5 - 3 mm in diameter, possibly with a narrowed insertion tip or narrowed internal diameter to facilitate the delivery of a spray, is inserted into the urethra 0.5 to 2 cm and a bolus or spray of about 0.1 cc to 1 cc of a solution containing 0.1 to 4.0 mg PGE<sub>2</sub> is placed in the urethra.

A first embodiment of the drug delivery device, shown in Figure 1,  
30 comprises a wand 10 which is sized to be placed within the urethra of the penis. The wand has an insertable portion 12 which, in use, resides in the

- 13 -

urethra, and a holding portion 14 for grasping by the user during insertion. The insertable portion 12 has a partial or complete covering of PGE<sub>2</sub> in a suitable carrier 16.

Figure 2 shows the wand 10 in cross section. The wand is shown as porous, with pores 18, the PGE<sub>2</sub>, with or without a carrier, 16 being both on the surface of the wand 10 and in the pores 18. The invention contemplates a nonporous wand 10 with the PGE<sub>2</sub> and carrier coated only on the surface as well as an alternate porous version with the PGE<sub>2</sub> and carrier being on both the surface as well as in the pores. The porous version allows delivery of more drug to the patient. However, because some of the drug is within the pores, the delivery rate for that portion may be slower than for the PGE<sub>2</sub> in the surface coating.

A second embodiment of the drug delivery device, shown in Figures 3 and 4, in addition to the features shown in Figures 1 and 2, has a handle 20 for grasping by the user during insertion and removal of the device. The shoulder 22 prevents the wand from being inserted too deeply.

A third embodiment, shown in Figures 5 and 6, instead of the shoulder 22, has a cap 24 to prevent insertion of the wand 10 to a depth greater than desired. In Figure 5, the cap is shown to have a curved profile similar to the rounded shape of the head of the penis. However, any shape is usable as long as the width of the cap is greater than the diameter of the urethra so as to prevent insertion of more than the desired length. Figure 6 shows the cap 24 as hemispherical in shape so that it can also serve as a cap to close a carrying container 26, such as shown in Figure 8. In the particular embodiment shown in Figures 5, 6 and 8, the cap 24 has threads 28 on its lower surface which can interact with similarly disposed threads 30 on the outer upper end of the container 26. In this manner the drug containing wand 10 can be inserted in the container 26 and closed and sealed, such as by a sonic or heat weld, to keep the PGE<sub>2</sub> from contamination or dissipation. It is also contemplated that the threads 28 can be replaced by other sealing

- 14 -

means such as snap rings or a friction fit, each of which may be further sealed by an externally applied adhesive tape (not shown).

Figure 7 shows a further variation of the embodiment of Figure 5 wherein the cap 24 is replaced by one or more extensions 32 which radiate outward from the wand 20 at the juncture of the insertable portion 12 and the holding portion 16. Figure 7 shows four extensions 32 which can be extended perpendicular to the wand 10 surface to be curved as in Fig. 5.

Figure 9 is an enlarged cut away view showing a further embodiment of the PGE<sub>2</sub> delivery device incorporating features shown in Fig. 7 placed within the male urethra. The porous wand 10 has the PGE<sub>2</sub> material in a suitable carrier 16 coated on the surface and in the pores of the wand. The insertion end of the wand 10 has a rounded tip 42 which has a diameter which approximates the diameter of the urethra. A length of the inserted portion 12 is coated with the PGE<sub>2</sub> and carrier composition 16, the composition or the PGE<sub>2</sub> alone also being carried in the pores 18 of the wand 10. As the PGE<sub>2</sub> coating melts or is absorbed, the diameter of the inserted coated portion decreases exposing the rear edge 44 of the rounded tip 42. As a result, when the wand 10 is removed from the urethra, the rear edge 44 acts as a wiper to remove excess PGE<sub>2</sub> and carrier from the urethra, thus substantially stopping the delivery of PGE<sub>2</sub> to the tissue of the penis. In this manner, the chance of overdose or transfer to the sexual partner during intercourse is greatly reduced or eliminated.

A delivery device 100 for the PGE<sub>2</sub> solution shown in Figure 10 consists of a tube 102 with an integral squeeze bulb 104. The dimensions of the device are chosen so that a unit dose 106 of PGE<sub>2</sub> in a suitable solvent is held within the length of the tube and adjacent portion of the squeeze bulb 104 and the squeeze bulb 104 can contain a volume of air 108 such that squeezing of the bulb 104 between two fingers will expel the unit dose. When some or all of the tube is inserted through the external opening of the urethra, squeezing the bulb results in droplet or spray delivery of the tube's contents along at least a portion of the length of the urethra downstream of the



- 15 -

inserted end of the tube 102. In one embodiment of the delivery device 100 the tube is from about 1.0 to 3.0mm in length, has an outer diameter of about 2.5mm and an inner diameter of about 1mm. This inner and/or outer diameter may be reduced at the insertable end of the tube to ease insertion and to create a spray of delivered product. The tube is able to contain about 0.01 to 0.03cc of liquid and the bulb is capable of delivering at least 0.1cc of air when compressed. However, the tube inner and outer diameter may be smaller and a portion or all of the unit dose may be in the bulb. This allows retention of about 0.01cc of a liquid in the lumen of the tube. Further, the delivery of the liquid composition is not limited to the use of the device of Figure 10. One skilled in the art is knowledgeable in the selection of a broad range of catheters for placement within the urethra.

Administration of the  $\text{PGE}_2$  may be accomplished by the transurethral placement of the wand to the desired depth. The  $\text{PGE}_2$  composition applied to the wand depends on whether a porous or nonporous wand is used. In the case of a porous wand, a liquid solution of the  $\text{PGE}_2$ , a carrier, and possibly an anesthetic and/or a transport adjuvant such as a meltable, swellable or soluble compound, is prepared and the wand is dipped in the solution until sufficient active material is deposited on and in the pores of the wand. This may be supplemented by a less fluid composition, with or without  $\text{PGE}_2$  applied to the surface of the wand, the surface composition preferably including a lubricant or having lubricating properties.

While transurethral delivery of  $\text{PGE}_2$  is a highly effective means of treating impotence, an undesirable side effect in some individuals is a sensation of urethral burning or pain and cavernous sinus aching in the genital area. One approach is to add a lubricant and/or a local anesthetic for desensitization thus masking these side effects. In one embodiment, the  $\text{PGE}_2$ , lubricant and anesthetic are all formulated into a convenient cream. This cream may be prepared, for example, by mixing one Upjohn Prostin E®  $\text{PGE}_2$  suppository together with 10 cc of a lidocaine jelly such as Xylocaine® 2% jelly (available from Astra Pharmaceutical Products) and 50 cc. of a

- 16 -

surgical lubricant such as K-Y jelly (available from Johnson & Johnson).

Lidocaine HC1, available in a variety of formulations, comprises acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl) -monohydrochloride.

The amount of lubricant and the amount and concentration of  
5 anesthetic can be varied considerably as will be apparent to one of skill in the art. For example, lidocaine jelly can be used having anywhere from about 1% to about 10% and preferably about 2% lidocaine. In general, the anesthetic level can largely be dictated by patient preference, as determined through routine experimentation. Although the incidence of adverse effects with  
10 Xylocaine® 2% jelly is very low, caution should be exercised when applying large amounts since the frequency of adverse effects is directly proportional to the total dosage of the local anaesthetic administered. See Astra Pharmaceuticals, product description 021838R11, June 1986; in Physician's Desk Reference, 45th Edition (1991), at p. 628.

15 A variety of other anesthetic agents can also be used with the formulation of the present invention, as will be appreciated by one skilled in the art. For example, novocaine, procaine, tetracaine or benzocaine may be selected. Patients allergic to para-aminobenzoic acid derivatives such as procaine, tetracaine and benzocaine have not appeared to show cross  
20 sensitivity to lidocaine. Lidocaine is also contraindicated in patients with a history of sensitivity to amide type local anesthetics. Xylocaine® 2% jelly also contains methylparaben, propylparaben and hydroxypropylmethylcellulose, as well as lidocaine; and, therefor, Xylocaine® is contraindicated for patients with known sensitivities to any of these compounds. See Astra Pharmaceuticals,  
25 product description 021838R11, June 1986; in Physician's Desk Reference, 45th Edition (1991), at p. 628.

As a result of adding the anesthetic to the PGE<sub>2</sub>, it has been discovered by the inventor that the effect of the PGE<sub>2</sub> treatment is generally less pronounced. Thus, in a lidocaine-containing formulation, the dosage of  
30 PGE<sub>2</sub> must be increased over that in a non-lidocaine-containing formulation, and more preferably, the PGE<sub>2</sub> dosage is preferably doubled in a lidocaine-

- 17 -

containing formulation in order to obtain the same effect on impotence. A further negative of adding an anesthetic is that it masks the pain rather than elevating the cause of the pain and may in fact reduce the pleasurable effects of intercourse by reducing tactile sensitivity. Similar dosage increases are  
5 required with PGE<sub>1</sub> but since PGE<sub>1</sub> appears to be less soluble in carriers than PGE<sub>2</sub>, adequate dosages of PGE<sub>1</sub> with anesthetic may not be readily prepared for delivery.

More or less lubricant may be desired depending upon the delivery dose and concentration of the anesthetic jelly. In general, the total volume of  
10 the impotence treating unit dose should be no more than 5 cc, and preferably from about 1 cc to no more than about 2 cc due to the inherent capacity of the urethra. Doses of excessive volume can result in painful administration, and also in retrograde migration of the excess formulation into the prostatic urethra or bladder.

15 Preferably, the total amount of PGE<sub>2</sub> contained in a unit dose will be within the range of from about 0.2 mg to about 5.0 mg. Due to differing etiology of erectile dysfunction, and inherent variations across a population in terms of responsiveness to pharmaceutical agents, some routine experimentation may be desired to determine optimum dosages for a given  
20 patient or class of patients.

In general, however, doses within the range of from about 0.2 to about 5.0 mg, and preferably from about 0.6 to about 3.6 mg PGE<sub>2</sub>, have generally proven sufficient in patients in which a response is likely to occur. Although it is not possible to predict with precision what types of patient populations will  
25 likely respond to the treatments disclosed herein, certain classes of patients are anticipated to be treatable depending upon the etiology of the condition. For example, patients in whom erectile dysfunction is associated with vascular abnormalities such as atherosclerosis which prevents adequate blood inflow are not likely to respond. Patients in whom the dysfunction is a  
30 result of such conditions as diabetes, denervation, or psychological status are expected to be more likely to respond. Where impotence is a result, although

- 18 -

undesired, of a surgical procedure, such as a prostatectomy, the efficacy of the treatment may depend on the vascular or nerve damage caused by the surgical procedure. However, clinical trials have shown the PGE<sub>2</sub> formulation is an effective treatment in many patients who show no, or an inadequate response to PGE<sub>1</sub> or Viagra®.


In the antidotal or priapism treating PGF<sub>2α</sub> formulation, the PGF<sub>2α</sub> will generally be present in an amount within the range of from about 5 to about 50 μg per 1 cc of formulation, preferably within the range of from about 8 to 20 μg/cc and more preferably about 12 μg/cc. As with the PGE<sub>2</sub> formulation, optimum dosage for a given patient can be determined through routine experimentation.

It has now been discovered that the burning, aching or cramping sensation can be eliminated without the use of an anaesthetic agent and the commensurate increase in PGE<sub>2</sub> to obtain the same effect. As described above, PGF<sub>2α</sub> reverses the effect of PGE<sub>2</sub>, i.e. terminates an erection. It has now been found that mixing small amounts of PGF<sub>2α</sub> with PGE<sub>2</sub> eliminates the burning or aching experienced by some individuals when PGE<sub>2</sub> is used alone. It has further been discovered that, unlike the addition of an anaesthetic to PGE<sub>2</sub>, adding PGF<sub>2α</sub> in small doses does not reduce the beneficial effects of PGE<sub>2</sub>, alleviates the cause of the pain rather than masking it and does not reduce the desirable sensory effects of intercourse. Further, additional amounts of PGE<sub>2</sub> are generally not required to obtain the same beneficial effects.

A suitable PGE<sub>2</sub> composition to eliminate the undesirable burning and aching sensation without noticeably reducing the impotence treatment effect of the PGE<sub>2</sub> includes from about 0.1μg to about 2.0μg of PGF<sub>2α</sub>. Below about 0.1μg the burning and aching may persist and above about 2μg and erection may occur more slowly and may not be adequate for intercourse. A preferred composition includes about 0.25μg of PGF<sub>2α</sub> for each milligram of PGE<sub>2</sub>.

It has been further discovered that addition of phentolamine mesylate

- 19 -



to PGE<sub>2</sub> increases the beneficial characteristics of the PGE<sub>2</sub> impotence treatment; namely rigidity and longevity of the erection. However, the urethral burning and cavernous sinus aching still persists. The addition of PGF<sub>2α</sub> to the combination, as in the case of addition to PGE<sub>2</sub>, eliminates this

5 undesirable side effect without reducing the enhanced benefits of the use of the phentolamine mesylate. A typical composition to produce an erection effective for intercourse comprises 1.0mg PGE<sub>2</sub> - 0.25μgm PGF<sub>2α</sub> and 0.25mg phentolamine mesylate in about 0.2cc of a suitable carrier, such as

10 sterile water. Smaller or larger doses, volumes or variations on the ratios of components may be used to adjust to particular patient response and disease etiology.

Any of several different delivery systems may be utilized in accordance with the method of the present invention. For example, a fluid, cream, gel system or solid suppository can be used and the carrier can be absorbed

15 directly, or allowed to be expelled following sufficient dwell time which may be controlled by occluding the distal end of the urethra.

Alternatively, more solid delivery vehicles may be used such as an ovoid or rod-shaped suppository. Suppositories can be formulated from any of a variety of materials which exhibit sufficient physical integrity to permit

20 transurethral insertion and which will then permit delivery of the medication. Once installed, the structural component of the suppository may break down under the influence of body heat. An advantage of applying the meltable composition to the surface of the wand is that the wand can be removed once the desired erection is achieved, thus terminating drug delivery, a procedure

25 not afforded by suppository products. Alternatively, the PGE<sub>2</sub> composition

- 20 -

placed in the pores of the wand can be protected until delivery by applying a sealing material on the surface of the wand, the sealing material melting or dissolving when placed within the urethra. As a further alternative, materials can be used which will dissolve in an aqueous environment at a pH within the  
5 range of that typical of the urethra. One suitable composition is a mixture of glycerides of fatty acids such as that used with the Prostin E<sub>2</sub>® product. Other suitable compositions include various cellulose based materials such as hydroxypropylmethylcellulose or collagen compositions which can be prepared as a fluid water-based material, a viscous solution, a gel or a water  
10 swellable dry coating. One skilled in the art can identify numerous physiologically acceptable water soluble materials or hydrogels which can be used for the purposes set forth above.

The above noted burning sensation is also experienced when using PGE<sub>1</sub>. It has been found that addition of PGF<sub>2α</sub> has substantially the same  
15 effect when added to PGE<sub>1</sub> in a percentage to total dosage equivalent to that used with PGE<sub>2</sub>.

As a further alternative, a variety of drug delivery vehicles may be used which neither dissolve nor break down in the environment of the urethra. Relatively rigid rod-shaped delivery vehicles may be fashioned from materials  
20 having a micro porous structure for the time release of entrapped pharmaceutical.

A major advantage of transurethral insertion of a wand is that it can be inserted for a predetermined period of time and then removed following delivery of an efficacious amount of drug. The removable time release  
25 delivery structure has the added advantage of providing a range of flexibility in the total delivered dose. Thus, the patient, by leaving the implant in place for relatively shorter or longer periods of time, can optimize the dose within a preset maximum range. A particular advantage of the cream, gel, or solution over prior disclosed pellets of drug containing compositions placed in the  
30 urethra is that the compositions disclosed herein can be readily dispersed along the length of the urethra allowing delivery through a large area of tissue

- 21 -

surface, thus reducing or eliminating the undesirable effects of delivering high dose concentrations to a very localized area, including slower dispersion, localized discomfort and less pronounced effectiveness.

Particular embodiments of the present invention will be described in  
5 the Examples which follow.

#### EXAMPLE I - Preparation of Intraurethral PGE<sub>2</sub> Cream

A batch of PGE<sub>2</sub> cream was prepared by mixing 40 mg of PGE<sub>2</sub> suppository (obtained as the "Prostin E<sub>2</sub>" suppository from the Upjohn Company) with 10 cc of 2% Xylocaine jelly and 50 cc of K-Y surgical  
10 lubrication jelly (hydroxyethyl-cellulose, obtained from Johnson & Johnson). Mixing was accomplished by stirring until the mixture appeared homogenous upon visual inspection. The result was a PGE<sub>2</sub> cream having approximately 1.3 mg of PGE<sub>2</sub> per 2 cc of cream. A portion of the cream was reserved for placement directly into the urethra while a second portion was applied to the  
15 surface of a wand. Approximately 2 cc of cream was applied to a 4 cm of the insertable length of a porous wand to produce a coated product 5 mm in diameter. This can be readily inserted and removed from the urethra.

#### EXAMPLE II - Preparation of Intraurethral PGE<sub>2</sub> Gel

The homogeneity of a bath of PGE<sub>2</sub> is ensured by inclusion of a  
20 methylene blue marker. One 20 mg PGE<sub>2</sub> suppository ("Prostin E<sub>2</sub>" from the Upjohn Company) is sliced into thin slices and allowed to soften at room temperature for 15 minutes. A small drop of 1% methylene blue solution (American quinine, Shirley, New York) is placed onto each slice to serve as a marker for homogeneity. The softened slices are thereafter geometrically  
25 mixed with the contents of a 56.7 gram tube of K-Y jelly to yield a homogenous mixture, as evidenced by blue color uniformity. The theoretical content of the final product is approximately 0.68 milligrams of PGE<sub>2</sub> per 2 cc of gel. A portion of the cream was reserved for placement directly into the urethra while a second portion was applied to the surface of a wand. The gel

- 22 -

was applied to 4 cm of the insertable length of a porous wand to produce an insertable product having a 3.0 to 5.0 mm diameter for insertion in the male urethra.

EXAMPLE III - Preparation of Lipid Based Intraurethral PGE<sub>2</sub> Cream

5           A batch of PGE<sub>2</sub> cream in cocoa butter is prepared by placing one 20 mg. PGE<sub>2</sub> suppository (Prostin E<sub>2</sub> by the Upjohn Company) into a porcelain evaporating dish and is melted in a 37° C water bath. Shredded cocoa butter is added to the melted suppository with stirring to bring the total mass to approximately 20 grams. As the melting continues, the temperature of the  
10       mixture is kept at or below about 33° C. Higher temperatures are to be avoided, as they have been reported to cause the crystalline form of the cocoa butter to change, resulting in aberrations in bioavailability. Transformations in the crystalline form of the cocoa butter are visually observed as a change from opalescent to transparent. After complete  
15       melting, the mixture is stirred thoroughly and a first portion poured into suppository molds. The material is thereafter allowed to cool at room temperature for about 15 minutes, and thereafter is placed in the refrigerator to facilitate further solidification. The suppositories may thereafter be  
20       removed from the mold, individually packaged and placed in refrigerated storage under anhydrous conditions.

          A second portion of the mixture was applied to 4 cm of the insertable length of a porous wand which was about 2 mm in diameter using a tubular mold. The material is thereafter allowed to cool at room temperature for about 15 minutes, and thereafter is placed in the refrigerator to facilitate  
25       further solidification in to 5 mm diameter coated wands. The coated wands are thereafter removed from the mold, individually packaged and placed in refrigerated storage under anhydrous conditions.



- 23 -

**EXAMPLE IV - Administration of Intraurethral PGE<sub>2</sub> Cream**

Two cc of the PGE<sub>2</sub> cream from Example I was instilled into the urethral meatus of each of 10 impotent male patients between the ages of 50 and 70, using a syringe. The cream was massaged down the urethra, and  
5 then the distal end of the urethra was occluded for 5 minutes by manual pressure.

**EXAMPLE V - Administration of Intraurethral PGE<sub>2</sub>**

Wands containing about 2cc of a PGE<sub>2</sub> composition prepared in accordance with Examples I - III placed within the urethra of males would be  
10 expected to cause full tumescence suitable for intercourse in a majority of the test subjects within about 15 minutes of placement of the wand at which time the wand can be removed, such removal terminating the delivery from the wand of the PGE<sub>2</sub>, except for small amounts which remain on the urethral mucosa.

15 **EXAMPLE VI - Efficacy of PGE<sub>2</sub> Cream in Treating Human Erectile Dysfunction**

The effect of administration of PGE<sub>2</sub> cream and the coated wand, prepared and administered in accordance with the procedures of Examples I and IV, was observed. After 15 to 30 minutes, treatment response was rated  
20 as no penile tumescence, partial tumescence or full tumescence.

As a result with the cream, two of the ten men treated had no response, six had partial tumescence, and two had full tumescence. Thus, 80% of the men treated showed at least partial penile tumescence in response to the intraurethral PGE<sub>2</sub> cream. Those treated with the cream  
25 treated wand would be expected to have a similar response.

- 24 -

EXAMPLE VII - Efficacy of Lower Concentrations of PGE<sub>2</sub> Cream in Treating Human Erectile Dysfunction

PGE<sub>2</sub> cream was prepared and administered in accordance with the procedures of Examples I and IV, except that a 20 mg PGE<sub>2</sub> suppository was used instead of a 40 mg suppository. This cream contained approximately 0.7 mg of PGE<sub>2</sub> per 2 cc of cream. Two cc of cream was used to treat each of ten impotent men between the ages of 50 and 70. After 15 to 30 minutes, treatment response was rated as no penile tumescence, partial tumescence, or full tumescence.

As a result, four of the ten men treated had no response, two had partial tumescence, and four had full tumescence. Thus, even using lower concentrations of PGE<sub>2</sub>, 60% of the men treated showed at least partial penile tumescence in response to the intraurethral PGE<sub>2</sub> cream. Those treated with the cream treated wand would be expected to have a similar response.

EXAMPLE VIII - Intraurethral Administration of a PGE<sub>2</sub> Hydrogel Composition

A wand carrying approximately 5 mg of PGE<sub>2</sub> in a hydrogel polymer carrier was placed into the urethral meatus of a 65 year old impotent male patient.

An effective erection resulted after 15 minutes at which point the wand was removed. Erection was sufficiently effective for intercourse. Detumescence commenced at approximately 1 hour after removal. Some PGE<sub>2</sub> remained in the wand after removal, the amount not being ascertained. As a result, an amount of PGE<sub>2</sub> less than 5 mg was delivered.

EXAMPLE IX - Use of PGF<sub>2α</sub> to Counteract Effects of Administration of PGE<sub>2</sub>

Priapism resulting from the use of an excess amount of PGE<sub>2</sub> has been determined to be reversible or treatable through the application of an effective antidotal amount of a 15 methyl substituted prostaglandin F<sub>2α</sub> containing formulation. In addition, it is anticipated that priapism from a

- 25 -

variety of other treatments for impotence (PGE<sub>1</sub> or Viagra®) will be similarly treatable.

An antidotal formulation is prepared by mixing approximately 250 micrograms of prostaglandin F<sub>2α</sub> obtained as Hemabate, marketed by Upjohn, in approximately 20 cc of K-Y jelly. Mixing is accomplished manually until visual observation reveals a homogenous composition. A dose of approximately 1 cc of the foregoing formulation was instilled into the urethra of an erect penis, to reverse the results of the PGE<sub>2</sub> treatment in accordance with the present invention. Following delivery of the PGF<sub>2α</sub> there is immediate relief of pain and within 5 minutes detumescence resulted.

EXAMPLE X - Use of a PGE<sub>2</sub>/PGF<sub>2α</sub> Combination to Treat Impotence

Freeze dried PGE<sub>2</sub> was obtained from Chinoin Pharmaceutical and Chemical Works Co. Ltd., Budapest, Hungary. Three different solutions were prepared with PGE<sub>2</sub> concentration being 0.5, 1.0 or 1.5 mg/ 0.1 cc of physiological saline. Samples were also prepared with the addition of PGF<sub>2α</sub> to the PGE<sub>2</sub> solution in the amount of 0.25μg/1.0mg PGE<sub>2</sub>. The several different solutions were instilled into the urethra of a normally impotent male at a distance of at least about 1 cc from the external opening of the urethra. An erection suitable for sexual intercourse occurred within about 3 to 5 minutes after placement of the solution and the erection lasted about 1 hour. In several instances the use of the PGE<sub>2</sub> solution resulted in a noticeable burning or aching feeling within the erect penis. No burning or aching was experienced in the solutions containing the PGF<sub>2α</sub> and the erectile effect and sustainability of the erection appeared to the treated individual to be undistinguishable from that of a control comprising a similarly prepared solution without the addition of the PGF<sub>2α</sub>. The only noticeable difference was the elimination of the burning sensation along the urethra encountered with the control solution. The 0.25 μg/1 mg concentration was found to be effective in most instances and the lesser concentrations were effective in fewer patients or produced a less satisfying result.

- 26 -

It has been further discovered that  $\text{PGE}_2$ , when applied to the mucous membrane of the introitus, labia minora, and/or clitoris of female external genitalia can also cause a physiological response reported to enhance sexual relations by causing engorgement of the treated tissue with blood in a manner similar to the creation of an erection in a male.

$\text{PGE}_2$  prepared in a cream in the same manner as described above, when applied to the external female genitalia, increases blood flow to the tissue treated which, in turn, causes a temporary swelling of the external genitalia to which applied and an enhanced sensitivity to external stimuli. A typical response is engorgement of the genitalia, redness, swelling and increased sensitivity typical of a normal response in an aroused female, the response occurring within about 10-15 minutes following application. A similar response results from use of  $\text{PGE}_2$  dissolved in a liquid carrier, such as water, when applied onto the genitalia or dispensed from a spray dispenser onto the external genitalia.  $\text{PGE}_2/\text{PGF}_{2\alpha}$  can also be used with a similar result. It is also believed that the addition of phentolamine mesylate will also have a beneficial effect.

In a study of several women using  $\text{PGE}_2$  prepared in a liquid comprising 1.0 mg  $\text{PGE}_2$  and 0.25  $\mu\text{g}$   $\text{PGF}_{2\alpha}$  in KY liquid (a water soluble, physiologically acceptable topical composition commercially available from Johnson & Johnson as a sexual lubricant) the women reported:

1. an increased pleasurable genital sensation
2. shortened time needed for foreplay to gain desirable stimulation
3. a higher incidence of orgasmic response reached within a shorter time period of stimulation and/or intercourse, and
4. a tightening of the external genitalia resulting in an increased stimulation on the erect penis of the sexual partner.

Although this invention has been described in terms of certain preferred embodiments, other embodiments that are apparent to those of ordinary skill in the art are also within the scope of the invention. In particular, analogs or derivatives of  $\text{PGE}_2$  and  $\text{PGF}_{2\alpha}$  which do not affect the basic

- 27 -

functionality of those molecules as described herein are also considered within the scope of the present invention. Accordingly, the scope of the invention is intended to be defined only by reference to the appended claims.

- 28 -

**What is claimed is:**

1. A method of enhancing sexual arousal of an individual comprising the step of administering to mucosal tissue of the genitalia of the individual a unit dose of a mixture of
  - a) a prostaglandin, said prostaglandin selected from the group consisting of  $\text{PGE}_1$ ,  $\text{PGE}_2$ , a physiologically acceptable salt thereof, a physiologically acceptable ester thereof, and mixtures thereof, and
  - b)  $\text{PGF}_{2\alpha}$ , a physiologically acceptable salt thereof, or a physiologically acceptable ester thereof, or a mixture thereof,the mixture of a) and b) above carried in a readily dispersible pharmaceutically acceptable delivery medium.
2. The method of claim 1 wherein sexual arousal comprises relieving erectile dysfunction in a male patient by delivering the mixture in a readily dispersible pharmaceutically acceptable delivery medium to the mucosa along a length of the urethra.
3. The method of claim 1 wherein the mixture of readily dispersible pharmaceutically acceptable delivery medium is applied to the mucosa of the external genitalia of a female patient.
4. The method of claim 2 or 3 wherein the unit dose contains from about  $0.5\mu\text{g}$  to about  $5.0\mu\text{g}$  of  $\text{PGF}_{2\alpha}$ .
5. The method of claim 2 or 3 wherein the unit dose contains about  $1\mu\text{g}$  of  $\text{PGF}_{2\alpha}$  for each milligram of the prostaglandin.

- 29 -

6. The method of claim 2 or 3 wherein the unit dose contains from about 0.5 $\mu$ g to about 5.0 $\mu$ g of PGF<sub>2 $\alpha$</sub>  and about 1 $\mu$ g of PGF<sub>2 $\alpha$</sub>  for each milligram of PGE<sub>2</sub>.

7. A composition for enhancing sexual arousal of an individual comprising a mixture of

a) a prostaglandin selected from the group consisting of PGE<sub>1</sub>, PGE<sub>2</sub>, a physiologically acceptable salt thereof, a physiologically acceptable ester thereof, and a mixture thereof, and

b) PGF<sub>2 $\alpha$</sub> , a physiologically acceptable salt thereof, or a physiologically acceptable ester thereof, or a mixture thereof

the mixture of a) and b) above carried in a pharmaceutically acceptable delivery medium readily dispersable to the mucosa tissue of the genitalia of the individual.

8. The composition of claim 8 wherein a unit dose thereof contains from about 0.5 $\mu$ g to about 5.0 $\mu$ g of PGF<sub>2 $\alpha$</sub> .

9. The composition of claim 7 wherein a unit dose thereof contains about 1.0 $\mu$ g of PGF<sub>2 $\alpha$</sub>  for each milligram of the prostaglandin.

10. The composition of claim 9 wherein a unit dose comprises 0.1cc to 0.5cc of a solution containing from about 0.2 to about 5.0mg of the prostaglandin.

11. The composition of claim 10 wherein the unit dose comprises 0.1cc to 0.5cc of a solution containing from about 0.5 to about 3.6mg of the prostaglandin.

- 30 -

12. The composition of claim 10 wherein the unit dose comprises 0.1cc of solution containing from about 0.5 to about 1.0mg of PGE<sub>2</sub>.


13. The composition of claim 11 wherein the unit dose thereof contains about 1.0µg of PGF<sub>2α</sub> for each milligram of erectile inducing prostaglandin.

14. The composition of claim 13 wherein the unit dose thereof contains about 1.0µg of PGF<sub>2α</sub> for each milligram of PGE<sub>2</sub>.

15. A delivery system for treating erectile impotence by delivery of a unit dose of an effective amount of a physiologically active composition to the mucosa of a male urethra comprising:

5 a urethral placement device containing the physiologically active composition, said device having at least a portion cylindrical in shape with an outer diameter approximating the diameter of the urethra and a length which limits insertion into the urethra to a predetermined depth;

the physiologically active composition being a compound having a structural formula:



10 or a physiologically acceptable salt or ester thereof, said physiologically active composition carried in a readily dispersable pharmaceutically acceptable delivery medium which allows a maximized, preferred localized effect, said delivery system alternatively comprising a rod with the physiologically active



- 31 -

15 composition in combination with the pharmaceutically acceptable delivery medium coated on the outer surface thereof or a hollow vessel with the physiologically active composition in a delivery medium carried therein for delivery through an attached tube into the urethra of the individual.

16. The delivery system for treating erectile impotence of claim 15 wherein the rod has pores therein, the pores being open to the surface of the rod, the physiologically active composition also being located in the pores in a such that it is transportable to the surface of the rod by the pharmaceutically acceptable delivery medium.

17. The delivery system for treating erectile impotence of claim 15 or 16 wherein the pharmaceutically acceptable delivery medium is selected from the group consisting of a material meltable at body temperature, a water soluble polymer and a water swellable polymer.

18. The delivery system for treating erectile impotence of claim 17 wherein the pharmaceutically acceptable delivery medium is selected from the group consisting of methylparaben, propylparaben, hydroxypropylmethylcellulose, glycerides of fatty acids, collagen, hydroxyethylcellulose and cocoa butter.

19. The delivery system for treating erectile impotence of claim 15 wherein the pharmaceutically acceptable delivery medium is liquid at body temperature.

20. The delivery system for treating erectile impotence of claim 15 wherein the pharmaceutically acceptable delivery medium is liquid at room temperature

- 32 -

21. The method of claim 1 wherein the mixture further includes phentolamine mesylate.

22. The method of claim 6 wherein the mixture further includes about 0.25 mg of phentolamine mesylate per 1.0mg of PGE<sub>2</sub>.

23. The composition for enhancing sexual arousal of claim 7 wherein the mixture further includes phentolamine mesylate.

24. The composition for enhancing sexual arousal of claim 10 wherein the mixture further includes about 0.25 mg of phentolamine mesylate per 1.0mg of PGE<sub>2</sub>.

25. The method of claim 21 wherein sexual arousal comprises relieving erectile dysfunction in a male patient by delivering the mixture in a readily dispersable pharmaceutically acceptable delivery medium to the mucosa along a length of the urethra.

26. The method of claim 1 wherein the mixture of readily dispersable pharmaceutically acceptable delivery medium is applied to the mucosa of the external genitalia of a female patient.

1/2




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6





Fig. 7

2/2



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 31/557, A61M 31/00</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/30718</b> <b>(43) International Publication Date:</b> 24 June 1999 (24.06.99)
<b>(21) International Application Number:</b> PCT/US98/26609 <b>(22) International Filing Date:</b> 15 December 1998 (15.12.98)  <b>(30) Priority Data:</b> 08/992,946 18 December 1997 (18.12.97) US 09/005,087 9 January 1998 (09.01.98) US 09/038,378 11 March 1998 (11.03.98) US  <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 08/992,946 (CIP) Filed on 18 December 1997 (18.12.97)  <b>(71)(72) Applicant and Inventor:</b> SCOTT, Nathan, Earl [US/US]; 610 Laguna Road, Fullerton, CA 92835 (US).  <b>(74) Agents:</b> RAM, Michael, J. et al.; Loeb & Loeb LLP, Suite 2200, 10100 Santa Monica Boulevard, Los Angeles, CA 90067 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 10 September 1999 (10.09.99)
<b>(54) Title:</b> PROSTAGLANDIN E <sub>2</sub> /F <sub>2α</sub> COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL		
<b>(57) Abstract</b>  A method of treating and a composition for treating erectile dysfunction in a male patient or female sexual arousal dysfunction, comprising the step of administering to the patient a unit dose of a formulation comprising an effective amount of a prostaglandin, namely prostaglandin E <sub>1</sub> , prostaglandin E <sub>2</sub> , or pharmaceutically acceptable salts or derivatives thereof, wherein the prostaglandin is formulated with a small amount of prostaglandin F <sub>2α</sub> together with a pharmaceutically acceptable delivery medium and/or a lubricant. The method also contemplates PGE <sub>2</sub> with phentolamine mesylate, with or without PGF <sub>2α</sub> .		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/26609

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 6 A61K31/557 A61M31/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 311 707 A (BIRNBAUM JAY E ET AL) 19 January 1982 *cf. abstract, col. 1, line 21, col. 2, lines 9-16, col. 13, example 11* ---	1-14, 21-26
X	US 3 917 864 A (KARIM SULTANALI M M) 4 November 1975 *cf. abstract, col. 2, lines 34-38, col. 4, example 1, lines 50-60* ---	1-14, 21-26
X	US 4 005 221 A (KARIM SULTANALI M M) 25 January 1977 *cf. col. 2, lines 22-35, col. 4, claim 1* ---	1-14, 21-26
Y	EP 0 357 581 A (AMSU LTD) 7 March 1990  *cf. abstract, page 3, lines 19-25, claims 1-11* ---	1-14, 21-26
-/-		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

12 July 1999

Date of mailing of the international search report

23. 07. 99

Name and mailing address of the ISA  
 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Stoltner, A

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/26609

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 93 00894 A (SCOTT NATHAN E) 21 January 1993 *cf. page 2, lines 9-15, page 3, lines 5-13, page 8, lines 7-18, example VII on page 14*	1-14, 21-26
	---	
X	US 5 482 039 A (PLACE VIRGIL A) 9 January 1996	15-20
Y	*cf. abstract, figures 1-8, col. 3, lines 29-35 and col. 4, lines 41-58*	1-14, 21-26
	---	
X	US 5 242 391 A (PLACE VIRGIL A ET AL) 7 September 1993	15-20
Y	*cf. abstract, figures 1-8, col. 3, lines 32-35*	1-14, 21-26
	---	
X	WO 91 16021 A (ALZA CORP) 31 October 1991	15-20
Y	*cf. abstract and figures 1-5*	1-14, 21-26
	-----	



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 98/26609

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-14, 21-26

A mixture for the treatment of impotence and for enhancing sexual arousal, comprising:

- a) a prostaglandin, said prostaglandin selected from the group consisting of PGE1, PGE2 and mixtures thereof, and
- b) PGF2-alpha

2. Claims: 15-20

A delivery system for treating erectile impotence comprising a urethral placement device

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/26609

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4311707 A	19-01-1982	EP 0015658 A	17-09-1980
		JP 55111417 A	28-08-1980
		ZA 7905932 A	25-03-1981
US 3917864 A	04-11-1975	NONE	
US 4005221 A	25-01-1977	NONE	
EP 0357581 A	07-03-1990	SE 463851 B	04-02-1991
		AT 91886 T	15-08-1993
		AU 638414 B	01-07-1993
		AU 4199489 A	02-04-1990
		CA 1335346 A	25-04-1995
		DE 68907909 T	23-12-1993
		DK 36491 A	01-03-1991
		EP 0432199 A	19-06-1991
		ES 2055677 T	01-09-1994
		FI 102454 B	15-12-1998
		GR 90300093 T	27-09-1991
		IE 62587 B	08-02-1995
		JP 7091199 B	04-10-1995
		JP 4501707 T	26-03-1992
		NO 301046 B	08-09-1997
		SE 8803087 A	03-03-1990
		WO 9002545 A	22-03-1990
		US 5849803 A	15-12-1998
		US 5843961 A	01-12-1998
		US 5886039 A	23-03-1999
WO 9300894 A	21-01-1993	AU 2300092 A	11-02-1993
		US 5708031 A	13-01-1998
US 5482039 A	09-01-1996	AU 2125195 A	17-10-1995
		BR 9507175 A	02-09-1997
		CA 2186382 A	05-10-1995
		CN 1124446 A	12-06-1996
		EP 0754006 A	22-01-1997
		FI 963798 A	22-11-1996
		JP 9510892 T	04-11-1997
		NO 963916 A	21-11-1996
		WO 9526158 A	05-10-1995
		US 5769088 A	23-06-1998
US 5242391 A	07-09-1993	US 5474535 A	12-12-1995
		US 5773020 A	30-06-1998
		AT 173603 T	15-12-1998
		AU 655420 B	22-12-1994
		AU 7856391 A	11-11-1991
		CA 2040914 A	26-10-1991
		DE 69130529 D	07-01-1999
		DE 69130529 T	02-06-1999
		EP 0526566 A	10-02-1993
		ES 2124225 T	01-02-1999
		FI 924817 A	23-10-1992
		NO 300083 B	07-04-1997
		NZ 237899 A	24-03-1997
		NZ 270871 A	28-05-1999
		PT 97441 A,B	29-05-1992

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/26609

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5242391 A		WO 9116021 A	31-10-1991
WO 9116021 A	31-10-1991	AT 173603 T	15-12-1998
		AU 655420 B	22-12-1994
		AU 7856391 A	11-11-1991
		CA 2040914 A	26-10-1991
		DE 69130529 D	07-01-1999
		DE 69130529 T	02-06-1999
		EP 0526566 A	10-02-1993
		ES 2124225 T	01-02-1999
		FI 924817 A	23-10-1992
		NO 300083 B	07-04-1997
		NZ 237899 A	24-03-1997
		NZ 270871 A	28-05-1999
		PT 97441 A,B	29-05-1992
		US 5474535 A	12-12-1995
		US 5242391 A	07-09-1993
		US 5773020 A	30-06-1998